Peptide Drug Regulatory Pathways — FDA, EMA, and PMDA Frameworks

Executive Summary

The regulatory approval of peptide-based therapeutics involves navigating a complex landscape of pathways across the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Peptide drugs occupy a unique regulatory position — straddling the boundary between small-molecule pharmaceuticals and large biologic products — which creates distinct pathway options including traditional New Drug Applications (NDA) under Section 505(b)(1), abbreviated pathways under 505(b)(2), and Biologics License Applications (BLA) under Section 351(a) of the Public Health Service Act. This article provides a comprehensive examination of each major regulatory pathway applicable to peptide therapeutics, including expedited programs such as Breakthrough Therapy Designation, Fast Track, Priority Review, and Accelerated Approval. Understanding these pathways is essential for sponsors seeking to bring peptide-based therapies from preclinical development through marketing authorization efficiently and compliantly.

Background

The regulation of therapeutic peptides has undergone profound evolution since the early 20th century, when the first peptide hormone preparations — crude extracts of insulin from animal pancreata — were introduced into clinical practice. The modern regulatory framework for peptide drugs began to crystallize with the passage of the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938, which established the requirement for pre-market safety demonstration, and was substantially strengthened by the Kefauver–Harris Amendments of 1962, which added the requirement for proof of efficacy through adequate and well-controlled clinical investigations.

The Drug Price Competition and Patent Term Restoration Act of 1984 (commonly known as the Hatch–Waxman Act) fundamentally reshaped the landscape for peptide drug development by establishing the Section 505(b)(2) NDA pathway — an abbreviated route that permits sponsors to rely, in part, on published literature or the FDA's prior findings of safety and efficacy for an approved drug rather than conducting all studies independently. This pathway has proven particularly valuable for peptide therapeutics, where modifications such as improved formulation, alternative delivery routes, or minor sequence variations can leverage existing knowledge while still warranting independent marketing authorization.

The Biologics Price Competition and Innovation Act (BPCI Act) of 2009, enacted as part of the Affordable Care Act, further refined the regulatory framework by establishing an abbreviated licensure pathway for biological products shown to be biosimilar to or interchangeable with an FDA-licensed reference product under Section 351(k) of the Public Health Service Act. For certain peptide products — particularly those that fall within the statutory definition of a "biological product" as a "protein (except any chemically synthesized polypeptide)" — the BPCI Act determines whether the product is regulated as a drug under the FD&C Act or as a biological product under the PHS Act.

Internationally, the EMA was established in 1995, consolidating the activities of its predecessor bodies into a unified European regulatory system. The PMDA, established in 2004 through the integration of several Japanese regulatory organizations, has similarly developed peptide-specific guidance within the broader framework of the Pharmaceuticals and Medical Devices Act (PMD Act). The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) has played a critical role in harmonizing technical requirements across these jurisdictions, reducing duplicative testing, and accelerating global access to peptide therapeutics.

Regulatory Pathway Classification for Peptide Drugs

Determining the Appropriate Regulatory Pathway

The first critical determination in a peptide drug development program is whether the product will be regulated as a drug under the FD&C Act or as a biological product under the PHS Act. This classification depends on several factors, including the peptide's size, its method of manufacture (chemical synthesis versus recombinant expression), and — most importantly — whether the peptide falls within the statutory definition of "protein."

Under the FDA's interpretation, a "protein" is defined by the presence of specific amino acid polymers with defined sequences and sizes typically greater than 40 amino acids. The distinction between chemically synthesized polypeptides and recombinant proteins has been refined through guidance documents, including the FDA's March 2020 guidance "Definition of the Term 'Biological Product'" and the transition provisions of the Further Consolidated Appropriations Act of 2020, which amended the definition of biological product to include "chemically synthesized polypeptides" that are functionally equivalent to recombinantly produced versions. As of March 23, 2020, products containing chemically synthesized polypeptides that previously would have been regulated as drugs under the FD&C Act are now regulated as biological products under the PHS Act, provided they meet the criteria for "protein."

This means that a peptide of 35 amino acids produced by solid-phase peptide synthesis (SPPS) will be regulated as a drug under the FD&C Act and may follow the 505(b)(1) or 505(b)(2) NDA pathway. However, the identical sequence produced recombinantly in E. coli may be subject to regulation as a biological product under the PHS Act, requiring a BLA under Section 351(a). For biosimilar or interchangeable versions of biological peptide products, the 351(k) pathway applies.

Section 505(b)(1) NDA — The Traditional Pathway

The 505(b)(1) NDA is the traditional "stand-alone" New Drug Application pathway, so designated because the sponsor owns or has right of reference to all data required for approval. A 505(b)(1) application includes:

• Full reports of investigations demonstrating safety and effectiveness
• Chemistry, Manufacturing, and Controls (CMC) information
• Nonclinical pharmacology and toxicology data
• Comprehensive clinical data from Phase 1, 2, and 3 trials
• Proposed labeling
• Patent information and certifications

For novel peptide entities (new molecular entities, or NMEs) where the sponsor has conducted all preclinical and clinical studies independently, the 505(b)(1) pathway remains the standard approach. This is typical for de novo peptide therapeutics with novel amino acid sequences, novel mechanisms of action, and no existing FDA-approved reference product. The 505(b)(1) NDA provides the greatest scope of data exclusivity protection — 5 years for NMEs — and is often the preferred commercial strategy for innovative peptide therapeutics.

Section 505(b)(2) NDA — The Abbreviated Pathway

The 505(b)(2) NDA is a hybrid pathway that permits the applicant to rely, at least in part, on investigations not conducted by or for the applicant and for which the applicant has not obtained a right of reference. This pathway is particularly important for peptide drug development for several reasons:

Reformulation of existing peptide drugs: A sponsor may develop a once-weekly subcutaneous formulation of a peptide previously approved only as a daily injection. The 505(b)(2) application can reference the FDA's prior safety and efficacy findings for the reference listed drug (RLD), supplemented by bridging studies demonstrating comparable pharmacokinetics and pharmacodynamics.

Alternative delivery routes: Oral formulations of peptide drugs that were previously available only by injection represent one of the most active areas of 505(b)(2) development. Semaglutide's transition from injectable (Ozempic) to oral (Rybelsus) exemplifies this strategy, though semaglutide ultimately received separate 505(b)(1) NDAs.

New indications or patient populations: A peptide approved for adults may be developed for pediatric populations through 505(b)(2), referencing existing adult safety data while generating pediatric-specific information.

Combination products: Peptide products combined with delivery devices, or co-formulated with other active ingredients, frequently follow the 505(b)(2) route.

The 505(b)(2) pathway is generally more efficient than 505(b)(1), potentially requiring fewer clinical trials, shorter development timelines, and reduced costs. However, careful attention must be paid to patent certifications, exclusivity periods, and the scope of reliance on the reference product's data.

Section 351(a) BLA — The Biologics License Application

For peptide products classified as biological products, the Section 351(a) BLA pathway constitutes the standard route for original biologics. A 351(a) BLA must contain:

• Data demonstrating the product is "safe, pure, and potent"
• Full CMC information, including manufacturing process characterization and validation
• Nonclinical and clinical data establishing safety and efficacy
• Analytical comparability data if manufacturing changes occur during development

The 351(a) BLA provides 12 years of reference product exclusivity for the first approved biologic, which is substantially longer than the 5-year NME exclusivity provided by NDA approval. This extended exclusivity period has strategic implications for peptide sponsors considering the drug-versus-biologic regulatory classification of their products.

Section 351(k) BLA — The Biosimilar Pathway

The 351(k) pathway, established by the BPCI Act, enables an abbreviated licensure pathway for biological products demonstrated to be biosimilar to a reference product already licensed under Section 351(a). Key features include:

• Requirement to demonstrate biosimilarity through analytical, nonclinical, and clinical studies
• Data demonstrating that the proposed product is "highly similar" to the reference product
• No clinically meaningful differences in safety, purity, and potency
• Option to seek interchangeability designation (requiring additional data demonstrating that switching between products presents no additional safety or efficacy risk)

Expedited Development and Approval Programs

Fast Track Designation

Fast Track designation is available for drugs (including peptide therapeutics) intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Key benefits of Fast Track designation include:

• Rolling review: The sponsor may submit completed sections of an NDA or BLA for FDA review on an ongoing basis, rather than waiting for the complete application
• More frequent interactions with the FDA: Increased opportunities for meetings and written communication to discuss development plans, trial design, and data requirements
• Eligibility for Priority Review at the time of application submission
• Potential eligibility for Accelerated Approval based on surrogate or intermediate clinical endpoints

Peptide therapeutics targeting rare metabolic disorders, orphan cancers, or severe inflammatory conditions frequently qualify for Fast Track designation. Sponsors may request Fast Track designation at any time during the IND phase of development, but typically do so no later than the pre-NDA or pre-BLA meeting.

Breakthrough Therapy Designation

Breakthrough Therapy Designation was created by the FDA Safety and Innovation Act (FDASIA) of 2012 and represents a higher threshold than Fast Track. To qualify, a drug must be intended to treat a serious condition, and preliminary clinical evidence must demonstrate that the drug may provide substantial improvement over available therapy on one or more clinically significant endpoints.

Benefits of Breakthrough Therapy Designation include all Fast Track features, plus:

• Intensive FDA guidance on an efficient drug development program, beginning as early as Phase 1
• Organizational commitment from FDA senior managers to facilitate product development
• Eligibility for Accelerated Approval and Priority Review

Peptide-based oncology therapeutics — including peptide-drug conjugates and peptide receptor radionuclide therapy (PRRT) agents — have been notable recipients of Breakthrough Therapy Designation. For example, the peptide receptor-targeted radiopharmaceutical lutetium Lu 177 dotatate (Lutathera) received Breakthrough Therapy Designation for gastroenteropancreatic neuroendocrine tumors and was subsequently approved through the NDA pathway.

Priority Review

Priority Review designation directs the FDA's attention and resources toward completing the review of an application within 6 months, rather than the standard 10-month review timeline. A drug is eligible for Priority Review if it would, if approved, provide a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition.

Priority Review is available for both NDAs and BLAs, including 505(b)(2) applications and biosimilar applications. The designation may be requested by the applicant or assigned by the FDA upon filing of the application. Peptide drugs demonstrating substantial efficacy advantages over existing therapies — such as dramatically improved A1C reduction or weight loss compared to standard-of-care treatments — are strong candidates for Priority Review.

Accelerated Approval

Accelerated Approval allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need, based on a surrogate endpoint that is reasonably likely to predict clinical benefit, or an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality. Products approved under Accelerated Approval are subject to post-marketing confirmatory trial requirements to verify and describe the anticipated clinical benefit.

The FDA's accelerated approval pathway has been used for multiple peptide-based products in oncology, where surrogate endpoints such as objective response rate or progression-free survival are reasonably likely to predict clinical benefit. Sponsors must commit to completing confirmatory trials with due diligence, and failure to confirm clinical benefit may result in expedited withdrawal proceedings.

Regulatory Landscape Across Major Jurisdictions

The following table summarizes the key regulatory pathway options for peptide therapeutics across the three major regulatory jurisdictions:

Regulatory Pathway	FDA (United States)	EMA (European Union)	PMDA (Japan)
Standard New Drug	505(b)(1) NDA	Full Marketing Authorization Application (MAA) under Directive 2001/83/EC	New Drug Application under the PMD Act
Abbreviated / Hybrid	505(b)(2) NDA	Hybrid application under Article 10(3) of Directive 2001/83/EC	Limited application with bridging data
Biologic Standard	351(a) BLA	Full MAA under Regulation (EC) No 726/2004	Biologics application under PMD Act
Biosimilar	351(k) BLA	Biosimilar MAA under Directive 2001/83/EC as amended	Biosimilar application under PMDA biosimilar guidelines
Accelerated Approval	Accelerated Approval (Subpart H)	Conditional Marketing Authorization (Regulation (EC) No 507/2006)	Conditional Early Approval System (Sakigake designation)
Priority Review	Priority Review (6 months)	Accelerated Assessment (150 days)	Priority Review (~9 months vs. standard 12)
Orphan Drug	Orphan Drug Designation (ODD)	Orphan Designation (Regulation (EC) No 141/2000)	Orphan Drug Designation under PMD Act

Current Understanding

The regulatory landscape for peptide therapeutics has matured substantially over the past two decades, with all three major regulatory agencies — FDA, EMA, and PMDA — now maintaining well-developed frameworks that accommodate the unique characteristics of peptide products. The distinction between chemically synthesized peptides (regulated as drugs) and recombinant polypeptides (regulated as biologics) represents a functional equilibrium that balances regulatory oversight with scientific rationale, though the transition provisions of the Further Consolidated Appropriations Act of 2020 have shifted certain chemically synthesized polypeptides into the biologics category.

The convergence of regulatory standards through ICH harmonization has significantly reduced duplicative testing requirements and facilitated global development programs for peptide therapeutics. Sponsors can now design single development programs that satisfy the requirements of multiple jurisdictions, though important region-specific requirements — such as the PMDA's requirement for Japanese clinical data in certain circumstances — must still be accommodated.

The expedited program landscape continues to evolve. The FDA's Breakthrough Therapy Designation has proven particularly valuable for peptide-based therapies in areas of high unmet need, while EMA's PRIME (PRIority MEdicines) scheme and PMDA's Sakigake (pioneering) designation provide analogous mechanisms for accelerated development support in their respective jurisdictions. The scientific consensus is increasingly supportive of biomarker-driven, adaptive clinical trial designs for peptide therapeutics, which align well with the flexibility inherent in expedited program frameworks. The RPL Peptide Data Center provides reference information on peptide products and their regulatory classifications that can support pathway selection and development planning. Researchers can access the RPL Peptide product catalog for research-grade peptides suitable for analytical development and preclinical regulatory studies.

Future Research Directions

• Harmonization of peptide-specific guidances: Despite broad ICH harmonization, peptide-specific quality guidances remain fragmented across jurisdictions. The development of an ICH-wide guideline specifically addressing the quality attributes of synthetic peptides would substantially reduce regulatory uncertainty.
• Advanced manufacturing technologies: The regulatory acceptance of continuous manufacturing, process analytical technology (PAT), and real-time release testing (RTRT) for peptide API production remains an active area of policy development. Sponsors and regulators must collaborate to establish validation frameworks for these advanced approaches.
• Artificial intelligence in regulatory submissions: The application of machine learning and AI to CMC data packages, stability data modeling, and clinical outcome prediction represents an emerging frontier in regulatory science. The FDA's Emerging Technology Program provides a mechanism for exploring these innovations.
• Real-world evidence (RWE) and real-world data (RWD): The 21st Century Cures Act and subsequent FDA guidance have created a framework for incorporating RWE into regulatory decision-making. The application of RWE to peptide therapeutics — particularly for label expansion, post-marketing safety surveillance, and accelerated approval confirmatory studies — warrants systematic investigation.
• Peptide-drug conjugates and complex peptide products: As peptide therapeutics increasingly incorporate non-peptide components (cytotoxins, radionuclides, lipids, carbohydrates), new regulatory frameworks for characterizing these complex products and assessing their manufacturing consistency will be required.
• Global regulatory reliance and work-sharing: The WHO Collaborative Registration Procedure and similar reliance mechanisms offer opportunities to accelerate access to peptide therapeutics in low- and middle-income countries. Research on the operationalization and impact of regulatory reliance for peptide products could inform policy development at both national and multilateral levels.

Frequently Asked Questions

What is the difference between a 505(b)(1) and 505(b)(2) NDA for a peptide drug?

A 505(b)(1) NDA is a full, stand-alone application where the sponsor owns or has right of reference to all data required for approval. A 505(b)(2) NDA allows the sponsor to rely, in part, on published literature or the FDA's prior findings of safety and efficacy for an already-approved drug (the reference listed drug), supplemented by additional bridging studies conducted by the applicant. The 505(b)(2) pathway is frequently used for reformulated peptides, new delivery routes, or new indications of existing peptide drugs.

Is a chemically synthesized peptide regulated as a drug or a biologic?

Under current U.S. law, a chemically synthesized polypeptide that is determined to fall within the statutory definition of "protein" is regulated as a biological product under the PHS Act as of March 23, 2020. Generally, peptides of fewer than 40 amino acids that are chemically synthesized remain regulated as drugs under the FD&C Act. However, the precise classification depends on the specific amino acid sequence, its relationship to naturally occurring proteins, and the FDA's determination of whether the product meets the definition of "protein." Sponsors should seek formal classification advice from the FDA early in development.

What expedited programs are available for peptide therapeutics at the FDA?

Four major expedited programs are available: (1) Fast Track Designation — for drugs treating serious conditions with unmet medical need, enabling rolling review and increased FDA communication; (2) Breakthrough Therapy Designation — requiring preliminary clinical evidence of substantial improvement over available therapy, with intensive FDA guidance; (3) Priority Review — shortening the review timeline from 10 months to 6 months for drugs offering significant improvement; and (4) Accelerated Approval — allowing approval based on surrogate endpoints reasonably likely to predict clinical benefit, with post-marketing confirmatory trial obligations.

How does the EMA's regulatory framework differ from the FDA's for peptide drugs?

The EMA operates through a centralized procedure (mandatory for certain product categories including biotechnology-derived products) under Regulation (EC) No 726/2004, as well as decentralized and mutual recognition procedures. The EMA's Conditional Marketing Authorization provides a mechanism analogous to FDA Accelerated Approval, and the PRIME scheme offers enhanced development support similar to Breakthrough Therapy Designation. Key differences include the composition of scientific advisory committees (CHMP vs. FDA Advisory Committees), the scope of orphan designation criteria, and the use of a single European Public Assessment Report (EPAR).

What is the PMDA's Sakigake designation and how does it apply to peptides?

Sakigake (meaning "pioneer" or "forerunner") is the PMDA's expedited development and review designation, established in 2015. It provides prioritized consultation, pre-application review, accelerated review (targeting 6 months rather than the standard 12 months), and extended re-examination periods. Sakigake is available for innovative peptide therapeutics that address serious diseases, demonstrate a notably higher efficacy or safety than existing treatments, and are intended for initial approval in Japan. The designation is limited to products from Japanese applicants or applicants with a Japanese development partner.

How long does regulatory exclusivity last for peptide drugs compared to biologics?

For drugs approved under an NDA, new chemical entities receive 5 years of exclusivity, while new clinical investigations supporting 505(b)(2) approvals may receive 3 years. For biologics approved under a BLA (351(a)), reference product exclusivity extends to 12 years, with an additional 4-year period during which a biosimilar application cannot be submitted. Orphan drug designation provides 7 years of market exclusivity for drugs and biologics alike, regardless of patent status. These exclusivity periods operate independently from any applicable patent protection.

Can a peptide drug receive both Fast Track and Breakthrough Therapy Designation?

Yes, but Breakthrough Therapy Designation subsumes all the benefits of Fast Track, so a product typically progresses from Fast Track to Breakthrough Therapy as clinical data mature. If preliminary clinical evidence emerges demonstrating substantial improvement over available therapy, the sponsor may request Breakthrough Therapy Designation for a product that already holds Fast Track. The Breakthrough Therapy Designation provides the enhanced benefit of intensive FDA organizational commitment and senior management involvement, which goes beyond what Fast Track alone provides.

What are the regulatory considerations for peptide-cytotoxin conjugates?

Peptide-drug conjugates (PDCs) and peptide-cytotoxin conjugates typically follow the NDA pathway under 505(b)(1) because they are combination products containing a drug component (the peptide targeting moiety) and another drug component (the cytotoxic payload). The FDA's Office of Pharmaceutical Quality (OPQ) and relevant clinical divisions coordinate reviews. CMC requirements include characterization of the conjugate ratio, free drug content, linker stability, and purity profile. Nonclinical safety evaluation must address both the intact conjugate and its components. PDCs may qualify for expedited programs if they address serious conditions with unmet medical need.

Does the PMDA require Japanese clinical data for peptide drug approval?

The PMDA strongly prefers the inclusion of Japanese subjects in global clinical development programs, consistent with ICH E5 (Ethnic Factors in the Acceptability of Foreign Clinical Data) and the subsequent E5 Implementation Working Group Q&As. While ICH E5 provides a framework for extrapolating foreign clinical data to a new region, bridging studies or specific Japanese Phase 1 or Phase 2 data are often required. For peptide therapeutics where ethnic sensitivity factors (e.g., receptor polymorphisms, metabolic enzyme differences) may be relevant, early engagement with the PMDA through clinical trial consultation (Jisedai Iryō Sōshutsu consultation) is recommended.

What is the role of the ICH in harmonizing peptide drug regulatory pathways globally?

The International Council for Harmonisation (ICH) develops guidelines adopted by regulatory authorities in the United States, European Union, Japan, and other ICH member countries. For peptide drugs, key harmonized areas include quality specifications (ICH Q6A/Q6B), stability testing (ICH Q1A-Q1E), impurity control (ICH Q3A-Q3B), genotoxicity testing (ICH S2), and clinical safety evaluation (ICH E1-E18). While ICH guidelines do not directly harmonize regulatory pathway designations, they ensure consistent technical requirements globally, enabling sponsors to generate single data packages acceptable across multiple jurisdictions.

References

1. U.S. Food and Drug Administration. (2020). Definition of the Term "Biological Product" — Guidance for Industry. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.
2. U.S. Congress. (2009). Biologics Price Competition and Innovation Act of 2009. Public Law 111-148, Title VII, Subtitle A.
3. European Medicines Agency. (2004). Regulation (EC) No 726/2004 of the European Parliament and of the Council. Official Journal of the European Union, L136, 1–33.
4. European Parliament and Council. (2001). Directive 2001/83/EC on the Community Code Relating to Medicinal Products for Human Use. Official Journal of the European Communities, L311, 67–128.
5. Pharmaceuticals and Medical Devices Agency. (2015). Strategy of SAKIGAKE — Scheme for Rapid Authorization of Innovative Medical Products. PMDA International Programs.
6. U.S. Food and Drug Administration. (2014). Guidance for Industry: Expedited Programs for Serious Conditions — Drugs and Biologics. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.
7. U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act (FDASIA). Public Law 112–144.
8. International Council for Harmonisation. (1998). ICH Guideline E5(R1): Ethnic Factors in the Acceptability of Foreign Clinical Data. ICH Harmonised Tripartite Guideline.
9. European Medicines Agency. (2006). Commission Regulation (EC) No 507/2006 on the Conditional Marketing Authorisation for Medicinal Products for Human Use. Official Journal of the European Union, L92, 6–9.
10. U.S. Food and Drug Administration. (1999). Guidance for Industry: Applications Covered by Section 505(b)(2). Center for Drug Evaluation and Research.
11. Lapteva, L., Purohit-Sheth, T., Serabian, M., & Puri, R. K. (2018). Clinical development of gene therapies: pre-clinical and clinical pharmacology considerations. Clinical Pharmacology & Therapeutics, 104(3), 468–474. DOI:10.1002/cpt.1166
12. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act). Public Law 98–417.
13. Pharmaceuticals and Medical Devices Agency. (2019). Points to Consider for Manufacturing and Quality Control of Synthetic Peptide Drugs. PMDA Notification.
14. European Medicines Agency. (2014). Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues. EMA/CHMP/BMWP/42832/2005 Rev. 1.
15. U.S. Food and Drug Administration. (2021). Guidance for Industry: Interchangeability for Biological Products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research.